Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies
Amy C Sherman(Dana-Farber Cancer Institute), Nicolas C. Issa(Dana-Farber Cancer Institute), Simon Doss-Gollin(Boston Children's Hospital), Guohai Zhou(Brigham and Women's Hospital), Yasmeen Senussi(Brigham and Women's Hospital), Simon D. van Haren(Boston Children's Hospital), Kinga K. Smolen(Boston Children's Hospital), Michaël Desjardins(Centre Hospitalier de l’Université de Montréal), Philippe Armand(Harvard University), Omolola Ometoruwa(Brigham and Women's Hospital), Rebecca Rooks(Brigham and Women's Hospital), Ofer Levy(Broad Institute), John Kupelian(Brigham and Women's Hospital), Chi‐An Cheng(Brigham and Women's Hospital), Jennifer L. Crombie(Dana-Farber Cancer Institute), David R. Walt(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Mikaela M. McDonough(Dana-Farber Cancer Institute), Liliana Guerrero(Dana-Farber Cancer Institute)
Cited by 10
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981